Antihyperlipidemic activity of amine cyanoboranes, amine carboxyboranes, and related compounds.
A series of amine cyanoboranes and amine carboxyboranes were observed to be antihyperlipidemic agents in mice; i.e., they lowered serum cholesterol and triglyceride levels significantly. These compounds appeared to inhibit lipid synthesis in the early stages. The ability to lower serum cholesterol levels appeared to correlate with the suppression of the regulatory enzyme of cholesterol synthesis, beta-hydroxy-beta-methylglutaryl-CoA reductase activity. The reduction of serum triglycerides correlated with ability of the borane compound to suppress liver fatty acid synthetase activity.
D000106:Acetate-CoA Ligase / Q000037:antagonists & inhibitors; D000596:Amino Acids / Q000494:pharmacology*; D000818:Animals; D001880:Boranes / Q000494:pharmacology*; D002784:Cholesterol / Q000096:biosynthesis; D005227:Fatty Acids / Q000096:biosynthesis; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D051379:Mice
D000596:Amino Acids; D001880:Boranes; D005227:Fatty Acids; D000960:Hypolipidemic Agents; D002784:Cholesterol; D000106:Acetate-CoA Ligase